Frontiers in bioinformatics · 2025
In silico analysis of CSF2RB from cancer genomic databases reveals a heterogeneous role in different breast cancer subtypes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alshelaiel Raghad, Alkushi Abdulmohsen, Alriyees Lolwah Abdullah, Alamro Abir Abdullah, Alanazi Humidah, Alhareeri Areej, AlMuzzaini Bader, Rashid Mamoon
Аннотация
OBJECTIVE: CSF2RB is the common beta chain of the heterodimeric receptors for the cytokines, granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 3 (IL-3), and interleukin 5 (IL-5). The activation of these cell surface receptors results in functional responses including cellular proliferation, differentiation, survival, and maturation via multiple signaling pathways such as JAK2/STAT5, MAPK, and PI3-kinase/AKT. Moreover, CSF2RB is abnormally expressed in a variety of tumors, especially in leukemia. The implications of CSF2RB in breast cancer remain unclear and have not been widely studied.
METHODS: We analyzed CSF2RB genetic changes, mRNA expression, DNA methylation, prognosis, and immune infiltration levels across different tumor types, with a focus on breast and hematological malignancies. The data used in this study were obtained from publicly available cancer genomics databases, such as TCGA, cBioPortal, TIMER2.0, GEPIA, and UALCAN.
RESULTS: Our in silico analyses showed overexpression of CSF2RB in acute myeloid leukemia (AML) and decreased expression in breast invasive carcinoma (BRCA) compared to matched normal samples. Promoter methylation of CSF2RB was elevated in BRCA samples compared to normal samples. Our analysis further demonstrates that the CSF2RB gene has a favorable prognostic effect in BRCA, although this was not statistically significant across all databases studied. We found that BRCA and its subtypes exhibit high CD8+ T-cell infiltration levels that are positively correlated with the CSF2RB gene expression level. Wild-type CSF2RB shows higher expression than the mutated CSF2RB in breast cancer. CSF2RB expression (and/or mutation) has no significant effect on the overall survival probability. CSF2RB expression is downregulated in luminal and HER2-positive samples but upregulated in triple-negative breast cancer (TNBC), compared to that in normal samples.
CONCLUSION: The results suggest a diverse role for the CSF2RB gene across different subtypes of breast cancer. To attribute a clear role to CSF2RB in breast cancer, further functional studies focusing on differential gene expression, methylation, and their prognostic effect in each breast cancer subtype are required.
METHODS: We analyzed CSF2RB genetic changes, mRNA expression, DNA methylation, prognosis, and immune infiltration levels across different tumor types, with a focus on breast and hematological malignancies. The data used in this study were obtained from publicly available cancer genomics databases, such as TCGA, cBioPortal, TIMER2.0, GEPIA, and UALCAN.
RESULTS: Our in silico analyses showed overexpression of CSF2RB in acute myeloid leukemia (AML) and decreased expression in breast invasive carcinoma (BRCA) compared to matched normal samples. Promoter methylation of CSF2RB was elevated in BRCA samples compared to normal samples. Our analysis further demonstrates that the CSF2RB gene has a favorable prognostic effect in BRCA, although this was not statistically significant across all databases studied. We found that BRCA and its subtypes exhibit high CD8+ T-cell infiltration levels that are positively correlated with the CSF2RB gene expression level. Wild-type CSF2RB shows higher expression than the mutated CSF2RB in breast cancer. CSF2RB expression (and/or mutation) has no significant effect on the overall survival probability. CSF2RB expression is downregulated in luminal and HER2-positive samples but upregulated in triple-negative breast cancer (TNBC), compared to that in normal samples.
CONCLUSION: The results suggest a diverse role for the CSF2RB gene across different subtypes of breast cancer. To attribute a clear role to CSF2RB in breast cancer, further functional studies focusing on differential gene expression, methylation, and their prognostic effect in each breast cancer subtype are required.